Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a gene-editing company’s disclosures can feel like graduate-level biology. Beam Therapeutics’ 10-K discusses base editing chemistry, while 8-Ks track trial pauses and collaboration payments—details that determine valuation yet hide in technical language. If you have ever searched "Beam Therapeutics SEC filings explained simply" and still felt lost, you are not alone.
Stock Titan turns those sprawling documents into clear insights. Our AI parses every Beam Therapeutics quarterly earnings report 10-Q filing, flags shifts in cash runway, and links pipeline milestones to revenue guidance. Need alerts on Beam Therapeutics insider trading Form 4 transactions? We stream Beam Therapeutics Form 4 insider transactions real-time so you can monitor executive stock moves before they hit the headlines. From a Beam Therapeutics annual report 10-K simplified to a Beam Therapeutics proxy statement executive compensation breakdown, each filing is auto-summarized, cross-referenced, and searchable alongside original EDGAR pages.
Use cases are practical: compare R&D spend quarter over quarter, study option grants in the Beam Therapeutics 8-K material events explained, or dive into licensing royalty terms—all without reading 300 pages. Whether you are a portfolio manager seeking "Beam Therapeutics earnings report filing analysis" or a researcher "understanding Beam Therapeutics SEC documents with AI," our platform delivers the context that drives informed decisions. Every filing, every update, right when it matters.
Saba Capital Income & Opportunities Fund (NYSE: BRW) has filed a shelf Registration Statement on Form N-2 seeking authority to issue up to 15,000,000 additional common shares and/or subscription rights and warrants. The Fund is a non-diversified, closed-end management investment company managed by Saba Capital Management, L.P.
Key portfolio facts (as of 30-Apr-2025):
- Net assets: $344.1 million; total assets (incl. leverage): $1.19 billion
- Shares outstanding: 42.53 million
- NAV: $8.09; market price: $7.68 (-5.1% discount)
- Leverage: $45 million drawn on a $125 million TD Bank credit facility (matures Jan-2026)
- Asset coverage on borrowings: 7,651%
Investment profile & strategy
- Primary objective: high current income; secondary objective: capital appreciation.
- Flexible mandate to invest in debt and equity of public & private issuers, including other closed-end funds, SPACs, high-yield bonds, CLOs, reinsurance notes and event-linked securities.
- Active use of leverage via direct borrowings, derivatives (options, swaps) and short sales.
Expense structure
- Management fee: 1.05% of Managed Assets.
- Total expense ratio after waivers: 6.55%; interest expense alone 3.79%.
- Expense Limitation Agreement cap (ex-leverage) in place until at least 1-Jul-2025.
Distribution policy
- Managed Distribution Plan pays a fixed $0.085 per share monthly; distributions may include return of capital.
Offering terms
- Securities may be sold from time to time directly, through agents or underwriters. Public offerings (other than certain rights offerings) cannot be priced below then-current NAV.
- Illustrative sales load: 3.0% of offering price; Fund bears offering expenses.
Risk highlights
- Material dilution risk: additional shares increase supply and may widen market discount if priced near NAV.
- High leverage amplifies NAV and distribution volatility, especially in rising-rate environments.
- Complex portfolio (high-yield, SPACs, CLO equity, catastrophe bonds) and 6.55% expense ratio elevate hurdle to generate positive total return.
- Distributions can draw heavily on return of capital, potentially eroding NAV over time.
The shelf registration provides the Adviser flexibility to raise capital quickly, potentially supporting portfolio scale and liquidity, but introduces execution and dilution concerns for existing shareholders.
Amendment No. 5 to Schedule 13D discloses that the Silver Lake–affiliated reporting persons (Global Blue Holding L.P., SL Globetrotter L.P., SL Globetrotter GP Ltd., Silver Lake Technology Associates III Cayman L.P. and Silver Lake (Offshore) AIV GP III Ltd.) have tendered all of their equity interests in Global Blue Group Holding AG (“GB”) in connection with the cash tender offer launched by Shift4 Payments, Inc. and its Swiss merger subsidiary.
The offer, which commenced on 21 March 2025 and expired one minute after 11:59 p.m. (NYC time) on 2 July 2025, met all conditions. The Silver Lake vehicles tendered:
- 34,871,499 ordinary shares held by Cayman Holdings at $7.50 per share
- 4,939,137 Series A preferred shares (convertible into ordinary shares) at $10.00 per share
- 91,230,811 ordinary shares held by Globetrotter at $7.50 per share
- 11,970,487 Series A preferred shares held by Globetrotter at $10.00 per share
In addition, 2,701,935 Global Blue warrants (Cayman Holdings) and 6,548,415 warrants (Globetrotter) were cashed-out and are no longer exercisable. As a result of these transactions, the reporting persons now report 0 shares beneficially owned (0.0% of the class) and thereby cease to be 5% holders as of 3 July 2025.
Following completion of the offer, director Joseph Osnoss resigned from the Global Blue board. The filing attaches an amended Annex A listing directors of the Silver Lake general partners and adds Exhibit 99.1 containing that information.
This amendment is limited to updating ownership, identity disclosures and purpose-of-transaction details; all other information in prior filings remains unchanged.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
What is Beam Therapeutics Inc. known for?
Which diseases does Beam Therapeutics target?
How does base editing differ from traditional gene editing?
What is the business model of Beam Therapeutics?
How does Beam Therapeutics integrate its technology into its clinical programs?
What role does research and development play at Beam Therapeutics?
How does Beam Therapeutics ensure the safety and efficacy of its therapies?
What differentiates Beam Therapeutics from its competitors in the gene editing landscape?
Is Beam Therapeutics focused on short-term financial performance?
How does Beam Therapeutics support its clinical research and operations?
